Wave Life Sciences Ltd.

Equities

WVE

SG9999014716

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-01 pm EST 5-day change 1st Jan Change
5.13 USD +6.65% Intraday chart for Wave Life Sciences Ltd. +16.33% +1.58%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Wave Life Sciences Ltd. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:00 PM
Leerink Partners Upgrades WAVE Life Sciences to Outperform From Market Perform, Price Target at $12 MT
Wave Life Sciences Starts Dosing in Neuromuscular Disorder Study MT
Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy CI
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday MT
Sector Update: Health Care MT
Investor Sentiment Muted Ahead of November Jobs Report, Driving Quiet Premarket Action for US Equity Futures MT
Top Premarket Decliners MT
WAVE Life Sciences Kicks off $100 Million Offering; Shares Plunge in Premarket Activity MT
Wave Life Sciences Ltd. Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency CI
Transcript : Wave Life Sciences Ltd., Q3 2023 Earnings Call, Nov 09, 2023
Wave Life Sciences Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (WVE) WAVE LIFE SCIENCES USA Reports Q3 Revenue $49.2M, vs. Street Est of $23.4M MT
Transcript : Wave Life Sciences Ltd. - Special Call
WAVE Life Sciences Submits First Clinical Trial Application for RNA Editing Candidate MT
WAVE Life Sciences Submits First Clinical Trial Application for RNA Editing Candidate MT
Wave Life Sciences Ltd. Announces Submission of First Clinical Trial Application for Wve-006 CI
Transcript : Wave Life Sciences Ltd., Q2 2023 Earnings Call, Aug 03, 2023
Wave Life Sciences Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Earnings Flash (WVE) WAVE LIFE SCIENCES USA Reports Q2 Revenue $22.1M, vs. Street Est of $7.9M MT
Raymond James Initiates WAVE Life Sciences at Outperform Rating With $7 Price Target MT
Wave Life Sciences Ltd.(NasdaqGM:WVE) added to Russell Small Cap Comp Value Index CI
Wave Life Sciences Ltd.(NasdaqGM:WVE) added to Russell 3000 Index CI
Wave Life Sciences Ltd.(NasdaqGM:WVE) added to Russell 3000E Index CI
Wave Life Sciences Ltd.(NasdaqGM:WVE) added to Russell Small Cap Completeness Index CI
Chart Wave Life Sciences Ltd.
More charts
Wave Life Sciences Ltd. is a clinical-stage genetic medicines company. The Company is engaged in developing medicines across multiple therapeutic modalities using PRISM, its proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. The Company's ribonucleic acid (RNA)-targeting oligonucleotides is designed to correct disease-causing mutations, modulate protein activity, restore the production of functional proteins, or reduce the expression of disease-promoting RNAs or proteins. Its lead programs are designed to treat genetic diseases, including those in muscle, including Duchenne muscular dystrophy (DMD); liver, including alpha-1 antitrypsin deficiency (AATD); and the central nervous system (CNS), including Huntington's disease (HD), amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). These programs include WVE-N531, WVE-006, WVE-003, and WVE-004.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
5.13 USD
Average target price
9.214 USD
Spread / Average Target
+79.62%
Consensus
  1. Stock
  2. Equities
  3. Stock Wave Life Sciences Ltd. - Nasdaq
  4. News Wave Life Sciences Ltd.
  5. Sector Update: Health Care Stocks Mixed Pre-Bell Thursday
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW